Sign In
Buy DSGN
$13.74
+0.0400 (+0.292%)
At Close: Jun 23, 2026
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
08:00am, Thursday, 28'th May 2026
CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, tod
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
02:26pm, Monday, 18'th May 2026
Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday.
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
11:00am, Monday, 18'th May 2026
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing
CARLSBAD, Calif. , May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, wi
CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, wil
Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know
01:01pm, Monday, 11'th May 2026
Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript
03:11am, Thursday, 30'th Apr 2026
Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
04:01pm, Tuesday, 28'th Apr 2026
Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and S
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
04:01pm, Monday, 09'th Mar 2026
Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026
Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00
01:33am, Friday, 20'th Feb 2026
Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) have received an average recommendation of "Moderate Buy" from the five ratings firms that are covering the company, MarketBeat Rat
Design Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 18'th Feb 2026
CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, to
Design Therapeutics (NASDAQ:DSGN) Shares Gap Up – Here’s Why
02:34am, Sunday, 01'st Feb 2026
Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) gapped up prior to trading on Friday. The stock had previously closed at $10.13, but opened at $10.48. Design Therapeutics shares l
Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00
01:00am, Monday, 26'th Jan 2026
Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) has received an average recommendation of "Moderate Buy" from the five analysts that are covering the firm, Marketbeat Ratings reports. One a
Design Therapeutics (NASDAQ:DSGN) Trading Down 4.5% – Here’s Why
03:38am, Friday, 02'nd Jan 2026
Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report)'s stock price traded down 4.5% during mid-day trading on Wednesday. The company traded as low as $9.43 and last traded at $9.3540. 246,384 sh
